Format

Send to

Choose Destination
J Pharm Sci. 2019 Oct;108(10):3434-3442. doi: 10.1016/j.xphs.2019.05.028. Epub 2019 Jun 1.

Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice.

Author information

1
The Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52246.
2
Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198.
3
The Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52246. Electronic address: guohua-an@uiowa.edu.

Abstract

Small-molecule tyrosine kinase inhibitors (TKIs) are novel anticancer agents with enhanced selectivity and superior safety profiles than conventional chemotherapeutics. A major shortcoming in TKI therapy is the development of acquired resistance. An important resistance mechanism is reduced intracellular drug accumulation due to an overexpression of efflux transporters such as P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) in cancer cells. TKIs have dual roles as substrates and inhibitors of Pgp and BCRP; thus, combination TKI therapy could potentially reverse efflux transporter-mediated TKI resistance. In the present study, the effect of 14 TKIs on Pgp-, Bcrp1-, and BCRP-mediated afatinib efflux was investigated in vitro. Nilotinib was a potent inhibitor of Pgp, Bcrp1, and BCRP, with EC50 values of 2.22, 2.47, and 0.692 μM, respectively. Consequently, the pharmacokinetics of afatinib with and without the coadministration of nilotinib was determined in mice plasma and various tissues. Nilotinib increased afatinib AUC by 188% in plasma, and this altered tissue AUC by -38.8% to +221%. Nilotinib also decreased the clearance of afatinib by 65.3%, from 609 to 211 mL/h. Further studies are warranted to assess nilotinib's chemosensitizing effect in tumor xenograft models.

KEYWORDS:

P-glycoprotein; breast cancer resistance protein; combination therapy; efflux pumps; pharmacokinetics; tyrosine kinase inhibitors

PMID:
31163185
DOI:
10.1016/j.xphs.2019.05.028

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center